Interview with Dr. Mike Schaefers, Chief Commercial Officer at LTS
Dr. Mike Schaefers shares his initial reflections on the company’s hybrid proposition, how it supports customer demand, and how the LTS culture keeps patient need at its core.
LTS takes next step in its Growth Journey with the acquisition of Tapemark Inc.
LTS LOHMANN Therapie-Systeme AG announces the closing of the acquisition of Tapemark Inc. located in St. Paul, MN, USA.
LTS-Academy: OTF as a viable dosage form for pain relief
Our LTS Academy session reports on the latest research in the field of pain and ketamine.
S-ketamine oral thin film – population pharmacokinetics and pharmacodynamics of S-ketamine, S-norketamine and S-hydroxynorketamine
Ketamine is a versatile drug administered via various routes, predominantly intravenously, for a variety of indications, including anesthesia, pain relief and treatment of depression.
LTS invests more than 3 million euros in environmental protection at the Andernach site!
With a new regenerative thermal oxidizer, the company saves about 1.5 million kWh per year.
In vitro to in vivo: De-risking the critical path from laboratory to clinical trial for transdermal therapies
Even the Egyptians explored the topical application of creams for the treatment of skin diseases and for systemic pain relief.
LTS ACADEMY: Introducing Oral Thin Films as a viable dosage form for a pain relief
In our LTS Academy session we will report on the [...]
LTS is now part of the 5-HT family
We are happy to announce our new strategic partnership with the 5-HT Digital Hub - Chemistry & Health.
Interview with Julia Lodder-Gadaczek
Dr. Julia Lodder-Gadaczek, Director Analytical Development in-vitro studies, talks about her role leading one of the LTS laboratories and how in-vitro models and working practices are continually evolving to provide accelerated, expert support to development partners.
LTS announces appointment of Dr Mike Schaefers as Chief Commercial Officer
LTS LOHMANN Therapie-Systeme AG is pleased to announce the appointment of Dr. Mike Schaefers as Chief Commercial Officer (CCO) effective May 1, 2022.